Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A link to the webcast and slides for download will also be available on Takeda’s website at https://www.takeda.com/investors/ir-events/.
ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005289/en/
Contact information
Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Media Outside Japan
Holly Campbell
holly.campbell@takeda.com
+1 617-588-9013
Investor Relations:
Christopher O’Reilly
christopher.oreilly@takeda.com
+81 (0) 3-3278-2543
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities29.10.2025 16:35:00 EET | Press release
SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/ Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco. Through this collaboration, the two companies will jointly investigate prov
Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 15:30:00 EET | Press release
Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategic Leaders as companies that provide a ric
Andersen Consulting Adds Collaborating Firm Vivaldi29.10.2025 15:30:00 EET | Press release
Andersen Consulting announces a Collaboration Agreement with Vivaldi, a global business and brand strategy consultancy, strengthening the organization’s strategy and business transformation offerings. Founded in 1999, Vivaldi is known for its approach to converge brand, business, and technology to keep clients in their leadership position. Operating in the U.S., Europe, and Latin America, Vivaldi works with leading global companies to build strong market positions, accelerate innovation, and design customer-centric business models. In today’s fast-evolving world shaped by AI, platform dynamics, and continuous reinvention, Vivaldi helps clients reimagine how business value is created and captured. The firm’s multidisciplinary teams blend deep consumer insight and market foresight with strategic, creative, and financial rigor to deliver tailored solutions for growth, transformation, and long-term competitiveness across industries. “Today’s business landscape demands that organizations le
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota ®29.10.2025 15:00:00 EET | Press release
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring
GigaDevice GD32F5xx and GD32G5xx Software Test Libraries (STL) Receive TÜV Rheinland IEC 61508 Functional Safety Certification29.10.2025 15:00:00 EET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced that its GD32F5xx and GD32G5xx Software Test Libraries have received IEC 61508 SC3 (SIL 2/SIL 3) functional safety certification from TÜV Rheinland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029124621/en/ Certificate This milestone expands GigaDevice’s functional safety portfolio, which already includes the GD32H7 and GD32F30x STLs, and now covers a broad range of MCUs with Arm® Cortex®-M7, Cortex®-M4, and Cortex®-M33 cores. Building on this foundation, GigaDevice will continue to deliver high-performance and safety-focused hardware and software solutions for key applications such as industrial control, energy and power, and humanoid robotics. With the growing emphasis on safety across industries like industrial automation, functional safety has become a critical considerat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom